Literature DB >> 34258537

Lanthanum carbonate to control plasma and urinary oxalate level in type 1 primary hyperoxaluria?

Agnieszka Pozdzik1,2, Cristina David1, Jelle Vekeman3, Frederik Tielens3, Michel Daudon4,5.   

Abstract

INTRODUCTION: The therapy to reduce urinary oxalate excretion in primary hyperoxaluria type 1 is still required. CASE
PRESENTATION: A 37-year-old hemodialyzed man suffered from systemic oxalosis secondary to primary hyperoxaluria type 1 exhibited a drastic plasma oxalate decrease from 110 to 22 µmol/L two months after adjunction of lanthanum carbonate to classical treatment (intensive hemodialysis with pyridoxine). A 34-year-old woman with normal kidney function presented 10 years of bilateral kidney stones due to primary hyperoxaluria type 1 [hyperoxaluria (109.2 mg/24 h), plasma oxalate (56.0 µmol/L)]. The oxalate level remained uncontrolled despite of low oxalate-normal calcium diet, pyridoxine and increased water intake though the lanthanum carbonate adjunction resulted in significant decrease in plasma oxalate and oxaluria.
CONCLUSION: We report the lanthanum efficacy in reducing circulating and urinary oxalate levels in type 1 primary hyperoxaluria. Possible mechanism of observed falls in oxalate concentration would be a decrease in the intestinal absorption of oxalate.
© 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

Entities:  

Keywords:  kidney stones; lanthanum carbonate; nephrocalcinosis; oxalate; primary hyperoxaluria type 1

Year:  2021        PMID: 34258537      PMCID: PMC8255283          DOI: 10.1002/iju5.12296

Source DB:  PubMed          Journal:  IJU Case Rep        ISSN: 2577-171X


  18 in total

1.  Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.

Authors:  Pierre Cochat; Sally-Anne Hulton; Cécile Acquaviva; Christopher J Danpure; Michel Daudon; Mario De Marchi; Sonia Fargue; Jaap Groothoff; Jérôme Harambat; Bernd Hoppe; Neville V Jamieson; Markus J Kemper; Giorgia Mandrile; Martino Marangella; Stefano Picca; Gill Rumsby; Eduardo Salido; Michael Straub; Christiaan S van Woerden
Journal:  Nephrol Dial Transplant       Date:  2012-05       Impact factor: 5.992

Review 2.  The tubular epithelium in the initiation and course of intratubular nephrocalcinosis.

Authors:  Benjamin A Vervaet; Anja Verhulst; Marc E De Broe; Patrick C D'Haese
Journal:  Urol Res       Date:  2010-08-02

Review 3.  Primary hyperoxaluria type 1: still challenging!

Authors:  Pierre Cochat; Aurélia Liutkus; Sonia Fargue; Odile Basmaison; Bruno Ranchin; Marie-Odile Rolland
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

4.  CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update.

Authors:  Marie Dion; Ghada Ankawi; Ben Chew; Ryan Paterson; Nabil Sultan; Patti Hoddinott; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

5.  Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1.

Authors:  F Illies; K-E Bonzel; A-M Wingen; K Latta; P F Hoyer
Journal:  Kidney Int       Date:  2006-09-06       Impact factor: 10.612

6.  Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.

Authors:  Geert J Behets; Geert Dams; Stephen J Damment; Patrick Martin; Marc E De Broe; Patrick C D'Haese
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-06

7.  [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria.

Authors:  P Sikora; G E von Unruh; B Beck; M Feldkötter; M Zajaczkowska; A Hesse; B Hoppe
Journal:  Kidney Int       Date:  2008-03-12       Impact factor: 10.612

8.  Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.

Authors:  Sonia Fargue; Dawn S Milliner; John Knight; Julie B Olson; W Todd Lowther; Ross P Holmes
Journal:  J Am Soc Nephrol       Date:  2018-03-27       Impact factor: 10.121

Review 9.  Targeting kidney inflammation as a new therapy for primary hyperoxaluria?

Authors:  Cristina Martin-Higueras; Isis Ludwig-Portugall; Bernd Hoppe; Christian Kurts
Journal:  Nephrol Dial Transplant       Date:  2019-06-01       Impact factor: 5.992

Review 10.  Future treatments for hyperoxaluria.

Authors:  Zachary Burns; John Knight; Sonia Fargue; Ross Holmes; Dean Assimos; Kyle Wood
Journal:  Curr Opin Urol       Date:  2020-03       Impact factor: 2.808

View more
  1 in total

Review 1.  New therapeutics for primary hyperoxaluria type 1.

Authors:  Pegah Dejban; John C Lieske
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-09       Impact factor: 3.416

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.